Opinion|Videos|December 23, 2024
Examining Axatilimab in the AGAVE-201 Trial For cGVHD
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses how the mechanism of action of axatilimab, recently approved by the FDA for chronic graft-vs-host disease (cGVHD), involves targeting CSF1R to disrupt macrophage differentiation and reduce inflammation, and how the AGAVE-201 trial demonstrated strong efficacy and safety, which will influence clinical decision-making and potentially change the GVHD treatment landscape by offering a novel therapeutic option.
Advertisement
Video content above is prompted by the following:
- What did this abstract elucidate about the mechanism of action of axatilimab, which was approved by the FDA this year as a treatment for chronic graft-vs-host disease (cGVHD)?
- How will this abstract affect your clinical decision-making?
- The AGAVE-201 trial led to the approval of axatilimab for cGVHD. Discuss the methods and study design of this trial.
- What were the key efficacy and safety data seen in the AGAVE-201 trial with axatilimab?
- How do these results influence your clinical practice?
- How do you see the GVHD treatment landscape changing with the introduction of axatilimab?
Advertisement
Related to this article
Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance, PALM outcomes, and quality of life.
An international eDelphi panel of 62 dermatologists agreed on a 2-step algorithm for tapering psoriasis biologics.
Real-world data from CHEST 2026 show ETI improved lung function and BMI in children with CF aged 6 to 11, with the most gains in F508del homozygotes.
Birth centers are unavailable in 10 states, and 39% of birth center births are self-pay, as licensing and Medicaid pay limit access, a report finds.
ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.
Narcolepsy and idiopathic hypersomnia can go undiagnosed for years, and Epworth and RU-SATED screening help clinicians spot true sleepiness sooner.
At CHEST 2026, 3 speakers explained why respiratory medications stay expensive, assessed what recent federal, state, and industry fixes have achieved, and urged clinicians to use their voices on behalf of patients.
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
2
Patents, Rebates, and a Policy Patchwork Keep Inhalers Costly, Panelists Say
3
How Flatiron Health’s Network Chief Is Building the Future For (and With) Community Oncology Practices
4
CHEST: The Face of Lung Cancer Has Changed, but Screening, Care Have Gaps
5